TENAX THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$56.4M | -$19.5M | -$8.2M | $11.1M | -$32.7M |
| Operating expenses | $56.4M | $19.5M | $8.2M | $11.1M | $32.7M |
| Cash from operations | -$35.8M | -$14.8M | -$5.9M | -$11.4M | -$10.9M |
| Capital expenditure | — | — | — | $2,323 | $5,252 |
| Free cash flow | — | — | — | -$11.4M | -$10.9M |
| Total assets | $104.2M | $96.7M | $11.7M | $3.4M | $6.0M |
| Total liabilities | $7.2M | $4.7M | $3.6M | $1.9M | $1.7M |
Shares outstanding 26.5M · Free float 87.3%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.